title: Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.
abstract: We have previously shown that the major dog allergen Can f 1 contains seven T cell epitope regions, none of which was preferentially recognized. To identify the immune characteristics of Can f 1 epitopes and to verify their suitability for peptide-based allergen immunotherapy, short-term T cell lines were generated with epitope-containing peptides from peripheral blood mononuclear cells of Can f 1 skinprick test-positive allergic and healthy control subjects. The lines were examined for their proliferative capacity and cytokine production upon stimulation with the allergen peptide, a homologous peptide from human tear lipocalin (TL) and Can f 1 and TL proteins. Can f 1 peptides induced proliferation of T cells and gave rise to T cell lines with comparable efficiencies. In particular, the T cell lines of allergic subjects induced with p33-48 and p107-122 favoured the production of interferon-gamma and interleukin-10, respectively. A greater number of Can f 1-specific T cell lines were generated from allergic than from healthy individuals. Two p107-122-induced Can f 1-specific T cell lines also reacted to a homologous peptide of human TL. Our results suggest that several T cell epitope-containing peptides should be used in combination for specific immunotherapy in Can f 1 allergy.
authors.affiliation: Department of Clinical Microbiology, University of Kuopio, Kuopio, Finland. Anu.Immonen@uku.fi
authors.forename: Anu K
authors.initials: AK
authors.lastname: Immonen
authors.forename: Antti H
authors.initials: AH
authors.lastname: Taivainen
authors.forename: Ale T O
authors.initials: AT
authors.lastname: Närvänen
authors.forename: Tuure T
authors.initials: TT
authors.lastname: Kinnunen
authors.forename: Soili A
authors.initials: SA
authors.lastname: Saarelainen
authors.forename: Marja A
authors.initials: MA
authors.lastname: Rytkönen-Nissinen
authors.forename: Tuomas I
authors.initials: TI
authors.lastname: Virtanen
mesh_terms: D000485:Allergens / Q000276:immunology*; D000818:Animals; D052179:Antigens, Plant; D002460:Cell Line; D049109:Cell Proliferation; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005240:Feasibility Studies; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000485:Allergens; D052179:Antigens, Plant; D016207:Cytokines; D018984:Epitopes, T-Lymphocyte; D010446:Peptide Fragments; C091462:allergen Can f I; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma